KCNJ2 mutation in intractable ventricular arrhythmia with Andersen's syndrome

Pediatrics International

Volumn 47, Issue 2, 2005, Pages 220-223

  Takahashi, Tohru ^a   Tandai, Satoshi ^a   Toki, Tsutomu ^a   Sato, Takumi ^a   Eto, Shuji ^c   Sato, Akira ^a   Ueda, Tomomi ^a   Sato, Sumito ^a   Ichinose, Kouta ^a   Ito, Etsuro ^a   Yonesaka, Susumu ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NONE

Author keywords

Andersen's syndrome; Cardiac pacing; KCNJ2 gene; Nicorandil; Ventricular arrhythmia

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL; METOPROLOL; MEXILETINE; NICORANDIL; POTASSIUM CHANNEL BLOCKING AGENT; PROPRANOLOL; SODIUM CHANNEL BLOCKING AGENT;

ADULT; ANDERSEN SYNDROME; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; FACE DYSMORPHIA; FEMALE; GENE; GENE MUTATION; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HETEROZYGOSITY; HUMAN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; KCNJ2 GENE; LONG QT SYNDROME; PERIODIC PARALYSIS; PRIORITY JOURNAL; TORSADE DES POINTES;

ADOLESCENT; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC PACING, ARTIFICIAL; ELECTROCARDIOGRAPHY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE IV; HUMANS; MUTATION, MISSENSE; NICORANDIL; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 20244387989     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-200x.2005.02024.x     Document Type: Article

References (10)

1. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystole, and multiple developmental abnormalities: a new syndrome? Acta Paedriatr. Scand. 1971; 60: 559-64.
2. Tawil R, Ptacek LJ, Pavlakis SG et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann. Neurol. 1994; 35: 326-30.
3. Plaster NM, Tawil R, Tristani-Firouzi M et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105: 511-19.
4. Eldar M, Griffin JC, Van Hare GF et al. Combined use of beta-adrenergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J. Am. Coll. Cardiol. 1992; 20: 830-7.
5. Shimizu W, Kurita T, Matsuo K et al. Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation 1998; 97: 1581-8.
6. Tristani-Firouzi M, Jensen JL, Donaldson MR et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J. Clin. Invest. 2002; 110: 381-8.
7. Lopatin AN, Nichols CG. Inward rectifiers in the heart: an update on IK1. J. Mol. Cell. Cardiol. 2001; 33: 625-38.
8. Jongsma HJ, Wilders R. Channelopathies: Kir2.1 mutations jeopardize many cell functions. Curr. Biol. 2001; 11: R747-50.
9. Donaldson MR, Jensen JL, Tristani-Firouzi M et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 2003; 60: 1811-16.
10. Junker J, Haverkamp W, Schulze-Bahr E et al. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. Neurology 2002; 59: 466.